LPCN – Lipocine Inc
Lipocine Inc.LPCN
$2.87Name : Lipocine Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $15,355,533.00
EPSttm :
Lipocine Inc.
$2.87
1.71%$0.05Float Short %
1.36
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
EPS Last/This Y
EPS This/Next Y
Price
2.87
Target Price
6.75
Analyst Recom
1
Performance Q
-15.84
Relative Volume
1.97
Beta
1.32
Ticker: LPCN
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-04-14 | LPCN | 3.08 | N/A | N/A | 0 |
| 2025-04-15 | LPCN | 3.06 | N/A | N/A | 0 |
| 2025-04-16 | LPCN | 3.04 | N/A | N/A | 0 |
| 2025-04-17 | LPCN | 3.0001 | N/A | N/A | 0 |
| 2025-04-18 | LPCN | 3 | N/A | N/A | 0 |
| 2025-04-21 | LPCN | 3.05 | N/A | N/A | 0 |
| 2025-04-22 | LPCN | 3.08 | N/A | N/A | 0 |
| 2025-04-23 | LPCN | 3.14 | N/A | N/A | 0 |
| 2025-04-24 | LPCN | 3.0875 | N/A | N/A | 0 |
| 2025-04-25 | LPCN | 3.19 | N/A | N/A | N/A |
| 2025-04-28 | LPCN | 3.28 | N/A | N/A | N/A |
| 2025-04-29 | LPCN | 3.31 | N/A | N/A | 0 |
| 2025-04-30 | LPCN | 3.39 | N/A | N/A | 0 |
| 2025-05-01 | LPCN | 3.52 | N/A | N/A | 0 |
| 2025-05-02 | LPCN | 3.34 | N/A | N/A | 0 |
| 2025-05-05 | LPCN | 3.42 | N/A | N/A | 0 |
| 2025-05-06 | LPCN | 3.3182 | N/A | N/A | 0 |
| 2025-05-07 | LPCN | 3.3 | N/A | N/A | 0 |
| 2025-05-08 | LPCN | 3.2328 | N/A | N/A | 0 |
| 2025-05-09 | LPCN | 3.26 | N/A | N/A | 0 |
| 2025-05-12 | LPCN | 2.9657 | N/A | N/A | 0 |
| 2025-05-13 | LPCN | 2.87 | N/A | N/A | 0 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-04-14 | LPCN | 3.12 | - | - | 0.00 |
| 2025-04-15 | LPCN | 3.05 | - | - | 0.00 |
| 2025-04-16 | LPCN | 3.04 | - | - | 0.00 |
| 2025-04-17 | LPCN | 3.00 | - | - | 0.00 |
| 2025-04-18 | LPCN | 3.00 | - | - | 0.00 |
| 2025-04-21 | LPCN | 3.00 | - | - | 0.00 |
| 2025-04-22 | LPCN | 3.01 | - | - | 0.00 |
| 2025-04-23 | LPCN | 3.10 | - | - | 0.00 |
| 2025-04-24 | LPCN | 3.12 | - | - | 0.00 |
| 2025-04-25 | LPCN | 3.19 | - | - | 0.00 |
| 2025-04-28 | LPCN | 3.28 | - | - | 0.00 |
| 2025-04-29 | LPCN | 3.26 | - | - | 0.00 |
| 2025-04-30 | LPCN | 3.31 | - | - | 0.00 |
| 2025-05-01 | LPCN | 3.56 | - | - | 0.00 |
| 2025-05-02 | LPCN | 3.34 | - | - | 0.00 |
| 2025-05-05 | LPCN | 3.42 | - | - | 0.00 |
| 2025-05-06 | LPCN | 3.47 | - | - | 0.00 |
| 2025-05-07 | LPCN | 3.30 | - | - | 0.00 |
| 2025-05-08 | LPCN | 3.45 | - | - | 0.00 |
| 2025-05-09 | LPCN | 3.28 | - | - | 0.00 |
| 2025-05-12 | LPCN | 2.92 | - | - | 0.00 |
| 2025-05-13 | LPCN | 2.87 | - | - | 0.00 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-04-14 | LPCN | 0.00 | -10.57 | 1.47 |
| 2025-04-15 | LPCN | 0.00 | -10.57 | 1.47 |
| 2025-04-16 | LPCN | 0.00 | -10.57 | 1.47 |
| 2025-04-17 | LPCN | 0.00 | -10.57 | 1.47 |
| 2025-04-18 | LPCN | 0.00 | -10.57 | 1.47 |
| 2025-04-21 | LPCN | 0.00 | -10.57 | 1.47 |
| 2025-04-22 | LPCN | 0.00 | -10.57 | 1.47 |
| 2025-04-23 | LPCN | 0.00 | -10.57 | 1.47 |
| 2025-04-24 | LPCN | 0.00 | -10.57 | 1.47 |
| 2025-04-25 | LPCN | 0.00 | -10.57 | 1.47 |
| 2025-04-28 | LPCN | 0.00 | -10.60 | 1.39 |
| 2025-04-29 | LPCN | 0.00 | -10.60 | 1.39 |
| 2025-04-30 | LPCN | 0.00 | -10.60 | 1.39 |
| 2025-05-01 | LPCN | 0.00 | -10.60 | 1.39 |
| 2025-05-02 | LPCN | 0.00 | -10.60 | 1.39 |
| 2025-05-05 | LPCN | 0.00 | -10.74 | 1.39 |
| 2025-05-06 | LPCN | 0.00 | -10.74 | 1.39 |
| 2025-05-07 | LPCN | 0.00 | -10.74 | 1.39 |
| 2025-05-08 | LPCN | 0.00 | -10.74 | 1.39 |
| 2025-05-09 | LPCN | 0.00 | -10.74 | 1.39 |
| 2025-05-12 | LPCN | 0.00 | -10.60 | 1.36 |
| 2025-05-13 | LPCN | 0.00 | -10.60 | 1.36 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
Avg. EPS Est. Next Quarter
Insider Transactions
Institutional Transactions
-10.6
Beta
1.32
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
45
Growth Score
35
Sentiment Score
3
Actual DrawDown %
93
Max Drawdown 5-Year %
-93.9
Target Price
6.75
P/E
Forward P/E
PEG
P/S
4.18
P/B
0.8
P/Free Cash Flow
EPS
-1
Average EPS Est. Cur. Y
EPS Next Y. (Est.)
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-146.13
Relative Volume
1.97
Return on Equity vs Sector %
-23.6
Return on Equity vs Industry %
-6.7
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
Lipocine Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 16
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1111 (TLANDO XR), a next-generation long-acting oral product candidate for TRT; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the treatment of cirrhosis; LPCN 1154 to treat postpartum depression; LPCN 2101, a NAS candidate for women with epilepsy; and LPCN 2203, an oral candidate for management of essential tremor. It also develops LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of metabolic dysfunction-associated steatohepatitis; LPCN 2401 to improve body composition in obesity management; and LPCN 1107, an oral hydroxy progesterone caproate product indicated for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.
stock quote shares LPCN – Lipocine Inc Stock Price stock today
news today LPCN – Lipocine Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch LPCN – Lipocine Inc yahoo finance google finance
stock history LPCN – Lipocine Inc invest stock market
stock prices LPCN premarket after hours
ticker LPCN fair value insiders trading